Fierce Pharma

JANUARY 30, 2024

2seventy Bio has traveled a difficult path ever since it spun out from bluebird bio to work on cancer cell therapies. | 2seventy Bio has traveled a difficult path ever since it spun out from bluebird bio to work on cancer cell therapies. Now, the company is splitting in two once again, passing its R&D programs to Regeneron and going all-in on its Bristol Myers Squibb-partnered CAR-T Abecma.

240

240

Dominic Tyer

JANUARY 30, 2024

Successful customer engagement will require pharma companies to maintain a rigid focus throughout the journey

Pharma 130

Pharma Pharmaceutical Marketing 130

Fierce Pharma

JANUARY 30, 2024

A nasal gel version of the motion sickness drug scopolamine has failed to make the grade with the FDA. The U.S. | A nasal gel version of the motion sickness drug scopolamine has failed to make the grade with the FDA. The U.S. regulator has sent a complete response letter to Defender Pharmaceuticals, rejecting DPI-396 for the prevention of nausea and vomiting induced by motion.

FDA 228

FDA Pharma Pharmaceutical 228

MedCity News

JANUARY 30, 2024

Even just a year ago, we couldn’t fathom a cure for cancer. Now, we can. Artificial intelligence (AI) is rapidly transforming the healthcare industry, with its ability to process and analyze vast amounts of data. Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.

Side effects 125

Side effects Ethics Medical Patients 125

Advertisement

Distribution

Fierce Pharma

JANUARY 30, 2024

After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. How will it fare in latest round of GSK showdown?

270

270

MedCity News

JANUARY 30, 2024

A preview of ViVE 2024 offers a sneak peek at the agenda and how the Payer and Provider Connect meeting platform initiatives have been revamped to maximize the quantity and quality of meeting for healthcare executives.

Healthcare 108

Healthcare Healthcare 108

MedCity News

JANUARY 30, 2024

Chronic pain, an enduring concern for many older adults, is no longer confined to the traditional realm of pharmaceuticals. While traditional pain management methods like medication were once the go-to approach, alternative therapies are emerging as a viable and holistic approach to addressing this issue.

Management 108

Management Medical Pharmaceutical Education 108

pharmaphorum

JANUARY 30, 2024

Legislation filed in the US is seeking to block Chinese biotech companies from federal contracts on the grounds they are a national security concern

107

107

MedCity News

JANUARY 30, 2024

As key opinion leaders (KOLs), nurses can provide insights on unmet clinical needs, identify gaps in treatment options, and contribute to the development of better and more patient-centric solutions. Here are three core reasons why pharmaceutical companies should tap the power of nurses.

Pharma 106

Pharma Pharmaceutical Patients Biopharma 106

pharmaphorum

JANUARY 30, 2024

From today, a new feature added to the NHS App used in the UK will allow millions of people to submit and view prescriptions, in a bid to save time for patients and doctors. The digital prescription function, which does away with the need for paper scrip, was put through its paces in a pilot trial last year involving a million users of the app, now being used by three-quarters of the UK population or around 33.5 million people.

Prescription 97

Prescription Doctors Patients 97

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

JANUARY 30, 2024

Regeneron Pharmaceuticals is paying $5 million up front for 2seventy bio’s cancer drug pipeline. 2seventy will now focus on a cell therapy commercialized with partner Bristol Myers Squibb while Regeneron adds assets for its newly formed cell therapy division.

Pharmaceutical 105

Pharmaceutical Biopharma Pharma 105

European Pharmaceutical Review

JANUARY 30, 2024

The European Medicine Agency’s human medicines committee (CHMP) recommended marketing authorisations for the regulatory approval of three medicines at its January 2024 meeting last week. The CHMP recommended Exblifep (cefepime/enmetazobactam) as a treatment for complicated urinary tract infections, including pyelonephritis, hospital-acquired pneumonia, including ventilator associated pneumonia, and for treating bacteraemia caused by the aforementioned infections.

Medicine 96

Medicine Marketing Safety Pharmaceutical 96

MedCity News

JANUARY 30, 2024

Proven to offer cost-effective solutions, Real-Time Location Systems (RTLS) can ease operational burdens for efficiency and enhance the relationship between patients and caregivers, enabling a more human-focused experience for all.

Patients 98

Patients 98

European Pharmaceutical Review

JANUARY 30, 2024

Results from a Phase III, randomised, placebo-controlled clinical trial have for the first time in fifty years, demonstrated an overall survival benefit from an adjuvant therapy in kidney cancer. Pembrolizumab targets a “checkpoint” pathway that is key in enabling cancer cells to avoid being destroyed by the immune system. As a result, the immunotherapy drug supports the immune system’s T cells fight tumours, the researchers highlighted.

Patients 91

Patients Pharmaceutical 91

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

MedCity News

JANUARY 30, 2024

Anne Osdoit, CEO of Moon Surgical, explains how the Maestro System may be expanding the surgical robotics pie by bringing the capability to newer markets and how surgical robotics do not have to break the bank.

Marketing 98

Marketing 98

Pharmaceutical Technology

JANUARY 30, 2024

The EMA has accepted GSK’s regulatory application seeking expansion of its RSVvaccine, Arexvy, to include adults aged 50 to 59 years.

105

105

MedCity News

JANUARY 30, 2024

For the first episode of 2024, Senior Reporter Katie Adams discussed some executive hires, promotions and departures that recently took place in the healthcare world, as well as layoffs affecting the industry. We also hear from Kristin Myers, who recently became Northwell Health’s first chief digital officer.

Healthcare 95

Healthcare Healthcare 95

Pharmaceutical Technology

JANUARY 30, 2024

Vertex is planning to submit a new drug application to the FDA following the announcement of its Phase III programme meeting its primary endpoint.

FDA 96

FDA 96

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

MedCity News

JANUARY 30, 2024

Blue Shield of California Promise Health Plan is working with the GED Testing Service to help members earn a General Educational Development (GED) diploma for no cost. Members can register online and gain access to GED study materials in both English and Spanish.

Education 90

Education 90

pharmaphorum

JANUARY 30, 2024

Elon Musk’s Neuralink company has said it has implanted its wireless brain implant device into a human being for the first time

99

99

MedCity News

JANUARY 30, 2024

Valendo Health, the newest startup built at Redesign Health, launched on Tuesday. The startup partners with independent endocrinology practices and provides technology to help them thrive in value-based care arrangements.

85

85

PharmaTimes

JANUARY 30, 2024

Type 2 diabetes is estimated to affect 462 million people worldwide

113

113

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

pharmaphorum

JANUARY 30, 2024

Vertex Pharma says its much-anticipated non-opioid painkiller, VX-548, clears two phase 3 trials en route to an FDA filing later this year

FDA 80

FDA Pharma 80

PharmaTimes

JANUARY 30, 2024

Around one million adults in the UK visit their GP every year due to chest pain

90

90

PharmaVoice

JANUARY 30, 2024

Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

FDA 59

FDA Safety 59

PharmaTech

JANUARY 30, 2024

Various impurities can infiltrate the container closure system in pharmaceutical manufacturing. Understanding nitrosamines, elemental impurities, extractables, and leachables can help ensure the safety of the final product.

Pharmaceutical manufacturing 52

Pharmaceutical manufacturing Safety Pharma Manufacturing 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Evolve Your Success

JANUARY 30, 2024

Are you on the cusp of transitioning to a career in medical device sales but uncertain about the steps to take? This episode could inspire you to finally embark on that transformative journey. Samuel Adeyinka sits down with Aaron Kopfinger , who shares his remarkable journey from pharma to a thriving career in medical device sales. A graduate of the Medical Sales Career Builder Program, Aaron unveils the challenges he faced, the pivotal moments that led him to pursue a change, and the impactful

Medical sales 52

Medical sales Sales Medical Pharma 52

PharmaTech

JANUARY 30, 2024

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

Manufacturing 52

Manufacturing Marketing 52

Pharmaceutical Commerce

JANUARY 30, 2024

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

Insurance 52

Insurance Medicine Pharmaceutical 52

PharmaTech

JANUARY 30, 2024

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews an esteemed panel of experts from IPEC Americas about excipient grades.

Pharmaceutical 52

Pharmaceutical 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management